Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Riekse, Robert G.a; f | Li, Geb; f; * | Petrie, Eric C.b; f | Leverenz, James B.b; c; f | Vavrek, Darcyf | Vuletic, Simonae | Albers, John J.e | Montine, Thomas J.d | Lee, Virginia M.-Y.i | Lee, Michaelj | Seubert, Peterj | Galasko, Douglask | Schellenberg, Gerard D.a; g | Hazzard, William R.a; h | Peskind, Elaine R.b; f
Affiliations: [a] Department of Medicine, Division of Geriatric Medicine, University of Washington School of Medicine, WA, USA | [b] Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, WA, USA | [c] Department of Neurology, University of Washington School of Medicine, WA, USA | [d] Department of Pathology, Division of Neuropathology, University of Washington School of Medicine, WA, USA | [e] Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington School of Medicine, WA, USA | [f] Northwest Network VISN-20 Mental Illness Research, Education, and Clinical Center (MIRECC), VA Puget Sound Health Care System, Seattle, WA, USA | [g] Geriatric Research, Education, and Clinical Center (GRECC), VA Puget Sound Health Care System, Seattle, WA, USA | [h] Geriatrics and Extended Care, VA Puget Sound Health Care System, Seattle, WA, USA | [i] Department of Pathology, University of Pennsylvania, Philadelphia, PA, USA | [j] Elan Pharmaceuticals, South San Francisco, CA, USA | [k] Department of Neurology, University of California, San Diego, CA, USA
Correspondence: [*] Corresponding author: Ge Li, MD, PhD, VA Puget Sound Health Care System, S-116MIRECC, 1660 South Columbian Way, Seattle, WA 98108, USA. Tel.: +1 206 764 2485; Fax: +1 206 768 5456; E-mail: [email protected].
Abstract: Background: Treatment with HMG-CoA reductase inhibitors ("statins") has been variably associated with a reduced risk of Alzheimer's disease (AD) in epidemiologic studies and reduced amyloid-β (Aβ) deposition in animal models of AD. Putative neuroprotective effects of statins may vary in relation to their ability to penetrate into the central nervous system (CNS). Methods: We measured levels of cerebrospinal fluid (CSF) AD biomarkers following 14 weeks of treatment with simvastatin (a CNS permeant statin; n=10) at 40 mg/day or pravastatin (a CNS impermeant statin; n=13) at 80 mg/day in hypercholesterolemic subjects without dementia. Results: Simvastatin, but not pravastatin, reduced CSF levels of phospho-tau-181 (p-tau181) in all subjects. There were no differences in CSF levels of total tau, Aβ42, Aβ40, soluble amyloid β protein precursor (sAβPP) α or β, or F2-isoprostanes. Conclusions: Statins may modulate the phosphorylation of tau in humans and this effect may depend on the CNS availability of the statin. These results suggest another mechanism by which statins may act to reduce the risk of AD.
Keywords: Alzheimer's disease, statins, tau, clinical trial, CSF
DOI: 10.3233/JAD-2006-10408
Journal: Journal of Alzheimer's Disease, vol. 10, no. 4, pp. 399-406, 2006
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]